Amgen INC

Amgen Inc. disclosed a material cybersecurity incident involving unauthorized access and exfiltration of data from third-party cloud environments, though it currently assesses no material impact on financial condition or operations.

Amgen shareholders re-elected all 12 director nominees and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Amgen Inc. announced the retirement of CFO Peter Griffith, effective August 31, 2026, and the appointment of Thomas Dittrich as his successor.

Amgen announced the retirement of its Executive Vice President and Chief Technology Officer, David M. Reese, effective June 30, 2026, with responsibilities to be redistributed and organizational changes implemented.

Amgen Inc. successfully completed the issuance of $4 billion in senior unsecured notes with maturities ranging from 2031 to 2056.

Amgen announced robust double-digit revenue and EPS growth for 2025, while providing 2026 guidance and detailing pipeline advancements and competitive challenges.

Amgen Inc. announced robust third-quarter and year-to-date financial results, driven by significant product volume growth, despite increasing regulatory and market pricing pressures.

Amgen reports significant revenue and earnings growth in Q2 2025, driven by strong product volumes, while navigating increasing pricing pressures and ongoing legal challenges.

Amgen's Q1 2025 results show a 9% increase in total revenue, driven primarily by volume growth in key products.

Amgen's Q3 2024 results show a significant increase in revenue, primarily driven by the acquisition of Horizon Therapeutics and strong performance from key products, though operating expenses also rose substantially.

Amgen's second quarter 2024 results show a significant increase in revenue driven by the Horizon Therapeutics acquisition, but also a decrease in net income due to higher operating expenses and tax adjustments.

Amgen's first quarter results show a net loss driven by acquisition costs and investment losses, despite a significant increase in product sales.

Amgen's 2024 10-K filing highlights pipeline advancements, manufacturing expansions, and navigation of a complex regulatory environment, including the impact of the Inflation Reduction Act.

Amgen's 10-K filing outlines the company's registered securities, including common stock and senior notes, and details their associated rights and obligations.

Amgen Inc. director Amy E. Miles acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Amgen Inc. director Ellen J. Kullman acquired 665 shares of common stock through the immediate vesting of restricted stock units.

Amgen Inc. director Mary E. Klotman acquired 665 shares of common stock through an immediate vesting of restricted stock units.

Amgen Inc. director Tyler Jacks acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Amgen Inc. Director Omar Ishrak acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Amgen Inc. Director Charles M. Holley acquired 665 shares of common stock through the vesting of Restricted Stock Units.

Amgen Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on May 19, 2026, detailing strong 2025 performance in drug development, sales growth, and manufacturing investments.

Amgen reports record sales for multiple products, advancements in its research and development pipeline, and outlines key board recommendations for the upcoming annual meeting.

Amgen's 2025 proxy statement highlights a strong 2024 with record sales for many products and outlines key initiatives, including advancing clinical trials and expanding manufacturing capacity.

Amgen Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on May 23, 2025, with key proposals including the election of twelve directors, approval of executive compensation, and ratification of Ernst & Young LLP as independent accountants.

Amgen's 2025 proxy statement details the agenda for the annual meeting and highlights the company's strong 2024 performance, including record sales and pipeline advancements.

Amgen is reminding stockholders to vote on key proposals ahead of the Annual Meeting of Stockholders scheduled for May 31, 2024.

The Vanguard Group reported a 0% beneficial ownership in Amgen Inc. common stock following an internal realignment that disaggregated reporting.

The Vanguard Group filed an Amendment No. 10 to its Schedule 13G, reporting continued beneficial ownership of 10% of Amgen Inc.'s common stock.

BlackRock, Inc. has filed an Amendment No. 15 to its Schedule 13G, reporting a 7.6% beneficial ownership stake in Amgen Inc.'s common stock as of March 31, 2025.